Yu Xia

Osteoporosis and sarcopenia-related traits: A bi-directional Mendelian randomization study

Chao Liu, Ningyuan Liu, Yu Xia et al. · Frontiers in Endocrinology · 2022 · 61 citations · Full text

Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial (075)

Xiaohua Wu, Jiafu Ji, Hanmei Lou et al. · Gynecologic Oncology · 2022 · 60 citations

Cervical Cancer, Phase Ii Trial, Medicine +8

Safety and efficacy of intracoronary hypoxia-preconditioned bone marrow mononuclear cell administration for acute myocardial infarction patients: The CHINA-AMI randomized controlled trial

Xinyang Hu, Xin Huang, Qian Yang et al. · International Journal of Cardiology · 2015 · 40 citations · Full text

A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with standard therapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (R/M CC).

Jing Wang, Hanmei Lou, Hongbing Cai et al. · Journal of Clinical Oncology · 2022 · 40 citations

Metastatic Cervical Cancer, Cervical Cancer, Ak104 Monotherapy +13

Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201)

Yuqin Song, Keshu Zhou, Chuan Jin et al. · Frontiers in Oncology · 2022 · 18 citations · Full text